Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 10:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 640 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Transfusion Clear all
Completed Phase 3 Interventional Results available

Safety and Effectiveness of Two Blood Transfusion Strategies in Surgical Patients With Cardiovascular Disease

NCT00071032
View directory record Official record
Conditions
Anemia, Hematologic Diseases, Cardiovascular Diseases, Heart Diseases, Myocardial Infarction, Thromboembolism, Pneumonia, Cerebrovascular Accident
Interventions
Liberal (10 g/dL) Transfusion Strategy, Restrictive (Symptomatic) Transfusion Strategy
Biological
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
50 Years and older
Enrollment
2,016 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Oct 22, 2026, 10:47 AM EDT
Completed Not applicable Interventional

Transfusion Requirements in Cardiac Surgery III

NCT02042898
View directory record Official record
Conditions
Disorder; Heart, Functional, Postoperative, Cardiac Surgery
Interventions
Restrictive Transfusion Strategy, Liberal transfusion strategy
Other
Lead sponsor
Unity Health Toronto
Other
Eligibility
18 Years and older
Enrollment
5,028 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
8
States / cities
San Francisco, California • New Haven, Connecticut • Portland, Maine + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Oct 22, 2026, 10:47 AM EDT
Completed Phase 2 Interventional Results available

Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

NCT03011034
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Talacotuzumab, Daratumumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
St Louis, Missouri • Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Oct 22, 2026, 10:47 AM EDT
Completed No phase listed Observational

Packed Red Blood Cell Transfusion and Intestinal Blood Flow in Preterm Neonates

NCT01628133
View directory record Official record
Conditions
Intestinal Blood Flow
Interventions
ultrasound
Procedure
Lead sponsor
St. Louis University
Other
Eligibility
Up to 3 Months
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 20, 2014 · Synced Oct 22, 2026, 10:47 AM EDT
Recruiting Phase 3 Interventional

A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With α- or β-Non-Transfusion-Dependent Thalassemia

NCT07517133
View directory record Official record
Conditions
Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia
Interventions
Mitapivat, Placebo Matching Mitapivat
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
1 Year to 17 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
5
States / cities
Palo Alto, California • Atlanta, Georgia • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 22, 2026, 10:47 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluating People With Thalassemia: The Thalassemia Longitudinal Cohort (TLC) Study

NCT00661804
View directory record Official record
Conditions
Thalassemia
Interventions
Not listed
Lead sponsor
Carelon Research
Other
Eligibility
5 Years and older
Enrollment
416 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
10
States / cities
Los Angeles, California • Oakland, California • Stanford, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2011 · Synced Oct 22, 2026, 10:47 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

The Effects Of Therapeutic Plasma Exchange (TPE) On Age Related Biomarkers And Epigenetics

NCT06534450
View directory record Official record
Conditions
Aging
Interventions
Sham, Therapeutic Plasma Exchange, IVIG
Device · Drug
Lead sponsor
Dobri Kiprov
Industry
Eligibility
50 Years to 95 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Mill Valley, California
Source: ClinicalTrials.gov public record
Updated Aug 2, 2024 · Synced Oct 22, 2026, 10:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Assessment of Whole Blood Cold Stored Platelets

NCT02006368
View directory record Official record
Conditions
Healthy
Interventions
Blood Collection and autologous re-infusion
Other
Lead sponsor
Bloodworks
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 4, 2017 · Synced Oct 22, 2026, 10:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of ECO Conversion System For Red Blood Cells.

NCT00261274
View directory record Official record
Conditions
Anemia
Interventions
A-ECO, Saline
Biological
Lead sponsor
Velico Medical
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2005
U.S. locations
6
States / cities
New Haven, Connecticut • Minneapolis, Minnesota • Albuquerque, New Mexico + 3 more
Source: ClinicalTrials.gov public record
Updated May 27, 2020 · Synced Oct 22, 2026, 10:47 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Comparative Analysis of Biotinylated, Irradiated and 51-Chromium Radiolabeled Red Blood Cells for Analysis of Recovery and Survival After Autologous Transfusion

NCT07446647
View directory record Official record
Conditions
Healthy Volunteer Red Blood Cell Labeling Study; Not Disease Focused
Interventions
Biotinylated Red Blood Cells (BioRBC), Irradiated Biotinylated Red Blood Cells (Irradiated BioRBC), 51 Chromium Labeled Red Blood Cells (51Cr RBC), Technetium 99m Labeled Red Blood Cells (99mTc RBC)
Biological
Lead sponsor
Jose Cancelas
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Cincinnati, Ohio • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 22, 2026, 10:47 AM EDT
Withdrawn Not applicable Interventional

Study of Platelet Rich Plasma Drops to Moderate Clinically Significant Dry Eye

NCT05121493
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Platelet Poor Plasma Tear Drops, Platelet Rich Plasma Tear Drops
Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 22, 2026, 10:47 AM EDT
Completed Not applicable Interventional Results available

Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia

NCT02007863
View directory record Official record
Conditions
Leukemia, Myelodysplasia, Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia
Interventions
Umbilical Cord Blood Transfusion, Fludarabine, Busulfan, Melphalan
Procedure · Drug
Lead sponsor
University of Miami
Other
Eligibility
Up to 21 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 28, 2015 · Synced Oct 22, 2026, 10:47 AM EDT
Completed Not applicable Interventional Results available

Massive Iron Deposit Assessment

NCT01572922
View directory record Official record
Conditions
Iron Overload, Excessive Body Iron Burden
Interventions
R2*-UTE, R2*-GRE, Liver biopsy
Device · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Oct 22, 2026, 10:47 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

S-Nitrosylation (SNO) Therapy During Autologous Blood Transfusion

NCT03999229
View directory record Official record
Conditions
Transfusion Related Complication
Interventions
SNO, Normal Saline, Red Blood Cell
Drug
Lead sponsor
James Reynolds
Other
Eligibility
18 Years to 35 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 22, 2026, 10:47 AM EDT
Not listed Phase 2 Interventional

Brain Oxygenation-II

NCT05171881
View directory record Official record
Conditions
Cerebral Hypoxia
Interventions
Intervention for cerebral hypoxia
Other
Lead sponsor
Valerie Chock, M.D., M.S. Epi
Other
Eligibility
Up to 6 Hours
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
5
States / cities
Loma Linda, California • Palo Alto, California • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Oct 22, 2026, 10:47 AM EDT
Completed Phase 2 Interventional Results available

Darbepoetin Administration to Preterm Infants

NCT00334737
View directory record Official record
Conditions
Infant, Newborn
Interventions
Darbepoetin Alfa Injection, erythropoietin alfa injection, sham injection
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
1 Hour to 49 Hours
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
3
States / cities
Denver, Colorado • Ogden, Utah • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Oct 22, 2026, 10:47 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Adverse Effects of RBC Transfusions: A Unifying Hypothesis

NCT00838331
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Fresh blood, Aged blood
Biological
Lead sponsor
Emory University
Other
Eligibility
21 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 22, 2026, 10:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Donor Iron Deficiency Study - Red Blood Cells From Iron-deficient Donors: Recovery and Storage Quality

NCT02889133
View directory record Official record
Conditions
Iron Deficiency
Interventions
Iron-dextran, Saline, Blood Donation, 24-hour PTR
Drug · Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 75 Years
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Oct 22, 2026, 10:47 AM EDT
Completed Not applicable Interventional

Laser Photocoagulation in Twin to Twin Transfusion Syndrome

NCT02506049
View directory record Official record
Conditions
Twin to Twin Transfusion Syndrome
Interventions
S-LPC:Selective Laser Photocoagulation
Device
Lead sponsor
University of Tennessee
Other
Eligibility
16 Weeks to 27 Weeks · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
2
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 13, 2020 · Synced Oct 22, 2026, 10:47 AM EDT
Completed Not applicable Interventional

Delayed Cord Clamping in Preterm Neonates

NCT02478684
View directory record Official record
Conditions
Premature Birth of Newborn, Infant, Very Low Birth Weight, Delayed Separation of Umbilical Cord, Placental Transfusion
Interventions
30 Seconds of placental blood transfusion, 60 Seconds of placental blood transfusion
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
28 Weeks to 35 Weeks
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Oct 22, 2026, 10:47 AM EDT
Terminated Phase 2 Interventional Results available

Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS)

NCT01222195
View directory record Official record
Conditions
Leukemia
Interventions
Lenalidomide, Darbepoetin alfa
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Oct 22, 2026, 10:47 AM EDT
Terminated Phase 3 Interventional Results available

Stroke With Transfusions Changing to Hydroxyurea

NCT00122980
View directory record Official record
Conditions
Hemochromatosis, Cerebrovascular Accident, Anemia, Sickle Cell, Hematologic Diseases
Interventions
Red Cell Transfusions, Iron Chelation, Hydroxyurea, Phlebotomy
Procedure · Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
5 Years to 18 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
28
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Jacksonville, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 22, 2026, 10:47 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Hepatic Transplantation Registry

NCT05944042
View directory record Official record
Conditions
Identify More Accurate Predictive Models of Transplant Risk to Monitor and Evaluate New and Existing Patient Factors
Interventions
Observational Transplant Analysis
Other
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Oct 22, 2026, 10:47 AM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

The BENeFiTS Trial in Beta Thalassemia Intermedia

NCT04432623
View directory record Official record
Conditions
Beta Thalassemia Intermedia, Sickle Cell Disease
Interventions
Benserazide Only Product
Drug
Lead sponsor
Phoenicia BioScience
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
4
States / cities
Oakland, California • Boston, Massachusetts • Weston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Oct 22, 2026, 10:47 AM EDT